SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWellnex Life Regulatory News (WNX)

Share Price Information for Wellnex Life (WNX)

Share Price is delayed by 15 minutes
Get Live Data
4.25    0.00 (0.00%)
Bid:
4.00
Ask:
4.50
Spread: 0.50 (12.50%)
Market Cap: £3.10m
WNX Live PriceLast checked at - London Stock Exchange

Intraday Wellnex Life Share Chart

Board Changes

12 Mar 2026 07:00

RNS Number : 3731W
Wellnex Life Limited
12 March 2026
 

ASX/AIM Announcement 12 March 2026

 

Board Changes

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that Eric Jiang, currently Non-Executive Director of Wellnex Life, has been appointed by the Board as Interim Executive Chair, effective immediately.

Ash Vesali, who has served as Interim Executive Chair for an agreed six-month period, will transition to the role of Non-Executive Director, effective immediately.

Background and Strategic Context

Under Mr Vesali's leadership, the Company executed a strategic turnaround focused on transitioning to a leaner and more efficient operating model. The early benefits of this initiative are evident in the Company's recent trading updates, including improvements to capital management governance and consolidation of the Company's product portfolio. The Board acknowledges Mr Vesali's significant contributions and the effective progress achieved under his stewardship and is pleased that he will continue to serve as a Non-Executive Director, providing an orderly handover to Mr Jiang.

About Eric Jiang

Eric Jiang is an experienced public company director and corporate adviser with more than 25 years of experience in capital markets, corporate strategy and international business development, and has served on the Wellnex board since 2017. He has served on the boards of several ASX-listed companies and brings extensive expertise in governance, capital raising and strategic growth initiatives.

As announced on 21 October 2025, the Board commenced an executive search for a permanent Chief Executive Officer. The Board is pleased to advise that this process is at an advanced stage, and a further market update will be provided in due course.

Mr Ash Vesali, Non-Executive Director, commented:

"I am very pleased with the collective progress achieved over the past six months. Following my independent review of the Company, I was invited to join the Board to lead a turnaround mandate. This involved strengthening capital management governance and consolidating the product portfolio, which has delivered clear results. I look forward to continuing to serve on the Board as a Non-Executive Director and contributing to the Company's ongoing progress."

Mr Eric Jiang, Interim Executive Chair, commented:

"I am pleased to assume the role of Interim Executive Chair and to lead the Group in executing the turnaround strategy established by the Board. On behalf of the Board, I would like to thank Ash for his substantial contributions over the past six months and look forward to continuing to work with him in his capacity as Non-Executive Director."

Eric's remuneration will be $472,000 p.a. pro-rata for the period when he acts as Interim Executive Chair.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

 

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX) Reach Markets

Eric Jiang T: 1300 805 941

Non-Executive Chairman E: IR@reachmarkets.com.au

E: eric.j@wellnexlife.com.au  

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASFSSEEEMSELD
Date   Source Headline
12th Jun 20269:45 amRNSAppointment of Non-Executive Director
30th Apr 20267:30 amRNSQ3 FY26 Quarterly Update and Appendix 4C
23rd Apr 20267:00 amRNSExtension of Loan Repayment
21st Apr 20268:07 amRNSUpdate on loan repayment
7th Apr 202610:15 amRNSHolding(s) in Company
2nd Apr 20267:00 amRNSExtension of Haleon Licensing and Supply Agreement
27th Mar 20267:00 amRNSIssue of Shares
12th Mar 20267:00 amRNSBoard Changes
12th Mar 20267:00 amRNSBoard Changes
27th Feb 20267:30 amRNSHalf Yearly Report and Accounts
9th Feb 20267:00 amRNSCompany Update
29th Jan 20267:00 amRNSQ2 FY26 Quarterly Update and Appendix 4C
16th Jan 20267:00 amRNSMarket Update
15th Jan 20267:55 amRNSDirector/PDMR Shareholding
16th Dec 20257:30 amRNSTrading Update
27th Nov 20257:01 amRNSResults of AGM and Board Change
27th Nov 20257:00 amRNSWithdrawal of Resolution & Resignation of Director
27th Nov 20257:00 amRNSChair AGM Speech
10th Nov 20258:22 amRNSUpdate on Loan Repayment
3rd Nov 20257:00 amRNSUpdate on Loan Repayment
28th Oct 20257:18 amRNSNotice of Annual General Meeting
21st Oct 20257:00 amRNSResignation of CEO and Loan Repayment
20th Oct 20257:00 amRNSChairman’s letter - Shareholder Update
20th Oct 20257:00 amRNSQ1 FY26 Quarterly Report and Appendix 4C
3rd Oct 20257:12 amRNSIssue of Shares
1st Oct 20257:11 amRNSAppointment of Interim Executive Chairman
30th Sep 202510:31 amRNSAnnual Report for Year Ended 30 June 2025
22nd Sep 20257:00 amRNSCompany Update
19th Sep 20257:00 amRNSAppointment of Non-executive Chair
19th Sep 20257:00 amRNSExpanded Financing Facility
18th Sep 20257:00 amRNSAppointment of Storelink as NZ Distributor
15th Sep 20257:15 amRNSDirector Resignation
9th Sep 20257:25 amRNSAppointment of Non-Executive Chair
29th Aug 202510:12 amRNSAppendix 4E – Preliminary Final Report
15th Aug 20257:49 amRNSResignation of Joint CEO
1st Aug 20258:04 amRNSChange of Address
31st Jul 20257:33 amRNSQ4 FY25 Quarterly Report and Appendix 4C
2nd Jul 20257:13 amRNSDivestment of The Iron Company
19th May 20257:30 amRNSIssue of Shares
12th May 20252:00 pmRNSTrading Update
6th May 20257:09 amRNSBoard and Management Changes
14th Apr 20257:00 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSAppointment of Powermed Plus as UK Distributor
8th Apr 20257:46 amRNSQ3 FY25 Quarterly Report and Appendix 4C
28th Mar 202510:30 amRNSHolding(s) in Company
27th Mar 20257:00 amRNSResult of WRAP Retail Offer
25th Mar 202510:30 amRNSIssue of Equity - Pain Away vendor shares
21st Mar 20257:00 amRNSAdmission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.